Abstract
The development of a commercial route toward the JAK1 inhibitor abrocitinib is described. The application of a late-stage Lossen rearrangement provided the desired cis-diaminocyclobutane, which was...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have